Menu

Respiratory Syncytial Virus Efficacy Model

RSV infection is responsible for a significant number of respiratory diseases in infants and morbidity in elderly populations. The cotton rat (S. hispidus) is susceptible to non-adapted human RSV.

Animals are infected by intranasal inoculation with RSV-A2. This is a non-lethal model that has been used to successfully test RSV vaccine and therapeutic candidates leading to IND and clinical development. Model kinetics indicate peak viral burden at day 4 or 5 post challenge followed by recovery through day7.
The best indicator of efficacy is viral load at the peak of infection and lung viremia is an indicator of morbidity.

KEY FEATURES

Animal Background: Challenge Route: Intranasal (IN) Peak Viremia:
Cotton Rat Intranasal (IN) A2 4 Days
Other Readouts
viremia detection in various organs and serum, CPE Assay, HAI Assay, PRNT, Microneutralization assay, Pseudovirus neutralization assay, ELISA, Luminex, Flow cytometry, qRT-PCR

Description: Lung viremia data (plaque assay) collected from
cotton rats challenged with 1x LD90 of Respiratory syncytial virus
(A2) via the intranasal (IN) route.

Description: Lung viremia data (plaque assay) collected from
cotton rats challenged with 1x LD90 of Respiratory syncytial virus
(A2) via the intranasal (IN) route.

Strain

  • RSV-A A2
  • RSV-A Long
  • RSV-A 9320
  • RSV-A 18537
  • RSV-B WV 14617-85

Testing Available

  • Cotton Rat Efficacy, Viral Neutralization Assays
  • Viral Neutralization Assays
  • Viral Neutralization Assays
  • Viral Neutralization Assays
  • Viral Neutralization Assays